Dexcom (NSDQ:DXCM) said today that it inked a development deal with Eli Lilly (NYSE:LLY) to include its continuous glucose monitor in the insulin-maker’s connected delivery devices.
The pair plans to start clinical trials by the end of this year, adding that they hope to position the combination of their technologies as a comprehensive solution for people with diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post Dexcom, Lilly ink deal to combine CGM into smart insulin delivery device appeared first on MassDevice.